TY - JOUR
T1 - Circulating Tumor Cells in Stage IV Melanoma Patients
AU - Hall, Carolyn S.
AU - Ross, Merrick
AU - Bowman Bauldry, Jessica B.
AU - Upshaw, Joshua
AU - Karhade, Mandar G.
AU - Royal, Richard
AU - Patel, Sapna
AU - Lucci, Anthony
N1 - Funding Information:
Support: This work was supported by philanthropic funds, for which we thank our many generous donors including Sheila Prenowitz, the Kiefer family, the Simon and Linda Eyles Foundation, the Wintermann Foundation, and the Emma Jacobs Breast Cancer Foundation.
Publisher Copyright:
© 2018 American College of Surgeons
PY - 2018/7
Y1 - 2018/7
N2 - Background: Management of stage IV melanoma patients remains a challenge. In spite of promising new therapies, many patients develop resistance and progression. The aim of this pilot study was to determine if circulating tumor cells (CTCs) are associated with shortened (180-day) progression-free survival (PFS) after a baseline CTC assessment in stage IV melanoma patients. Study Design: A baseline CTC assessment was performed in 93 stage IV melanoma patients using a commercially available immunomagnetic system. The presence of 1 or more CTC was considered a positive result. A Cox multivariable regression model was used to evaluate the association between presence of CTCs at baseline and PFS, after adjusting for covariables. Kaplan-Meier curves and a log-rank test were used to summarize and compare unadjusted PFS for patients stratified by CTC positivity. Results: Median follow-up was 17 months; mean age was 55 years. Thirteen of 93 (14%) patients had no evidence of disease (NED) at baseline CTC assessment. One or more CTC was detected in 39 of 93 (42%) of patients at baseline; CTCs were not associated with primary melanoma features or NED status. Twenty-eight of 93 (30%) patients progressed within 180 days of baseline draw, with 20 of 39 (51%) of the CTC-positive patients relapsing compared with 8 of 54 (15%) of the CTC-negative patients. In adjusted Cox models, a significant association was found suggesting worse PFS within 180 days for CTC-positive patients at baseline (vs CTC-negative) (hazard ratio 4.69, 95% CI 1.59 to 13.77, p = 0.005). Conclusions: One or more CTCs at baseline were associated with progression within 180 days in stage IV melanoma patients. This information warrants further study of CTCs as a means of identifying patients at high-risk for disease progression.
AB - Background: Management of stage IV melanoma patients remains a challenge. In spite of promising new therapies, many patients develop resistance and progression. The aim of this pilot study was to determine if circulating tumor cells (CTCs) are associated with shortened (180-day) progression-free survival (PFS) after a baseline CTC assessment in stage IV melanoma patients. Study Design: A baseline CTC assessment was performed in 93 stage IV melanoma patients using a commercially available immunomagnetic system. The presence of 1 or more CTC was considered a positive result. A Cox multivariable regression model was used to evaluate the association between presence of CTCs at baseline and PFS, after adjusting for covariables. Kaplan-Meier curves and a log-rank test were used to summarize and compare unadjusted PFS for patients stratified by CTC positivity. Results: Median follow-up was 17 months; mean age was 55 years. Thirteen of 93 (14%) patients had no evidence of disease (NED) at baseline CTC assessment. One or more CTC was detected in 39 of 93 (42%) of patients at baseline; CTCs were not associated with primary melanoma features or NED status. Twenty-eight of 93 (30%) patients progressed within 180 days of baseline draw, with 20 of 39 (51%) of the CTC-positive patients relapsing compared with 8 of 54 (15%) of the CTC-negative patients. In adjusted Cox models, a significant association was found suggesting worse PFS within 180 days for CTC-positive patients at baseline (vs CTC-negative) (hazard ratio 4.69, 95% CI 1.59 to 13.77, p = 0.005). Conclusions: One or more CTCs at baseline were associated with progression within 180 days in stage IV melanoma patients. This information warrants further study of CTCs as a means of identifying patients at high-risk for disease progression.
UR - http://www.scopus.com/inward/record.url?scp=85047180502&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047180502&partnerID=8YFLogxK
U2 - 10.1016/j.jamcollsurg.2018.04.026
DO - 10.1016/j.jamcollsurg.2018.04.026
M3 - Article
C2 - 29746918
AN - SCOPUS:85047180502
SN - 1072-7515
VL - 227
SP - 116
EP - 124
JO - Journal of the American College of Surgeons
JF - Journal of the American College of Surgeons
IS - 1
ER -